Plasma miR-379 can predict treatment response to FOLFIRINOX and gemcitabine-nab-paclitaxel in advanced pancreatic cancer
Lenka N.C. Boyd(Amsterdam University Medical Centers), Geert Kazemier(European Organisation for Research and Treatment of Cancer), Luca Morelli(University of Pisa), Laura L. Meijer(Erasmus MC), Tessa Y. S. Le Large(Amsterdam University Medical Centers), Hanneke W.M. van Laarhoven(Dutch Cancer Society), Mahsoem Ali(Amsterdam Neuroscience), Elisa Giovannetti(University of Pisa), Jisce R. Puik(Amsterdam UMC Location Vrije Universiteit Amsterdam), Laura Ginocchi(Azienda Usl Toscana Centro), Ingrid Garajová(University of Parma), Adam E. Frampton(Hammersmith Hospital), Roberta Tartarini(Azienda Usl Toscana Centro), Andrea Mambrini, Annalisa Comandatore(University of Pisa), Marc G. Besselink(Amsterdam Neuroscience), Johanna W. Wilmink, Rutger‐Jan Swijnenburg(Amsterdam University Medical Centers)
Cited by 4
Related Papers
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial
|The Lancet Oncology|2015|2.6k
Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial
|Journal of Clinical Oncology|2020|1.1k
Endoscopic Transgastric vs Surgical Necrosectomy for Infected Necrotizing Pancreatitis
|JAMA|2012|735
Endoscopic or surgical step-up approach for infected necrotising pancreatitis: a multicentre randomised trial
|The Lancet|2017|732
United European Gastroenterology evidence‐based guidelines for the diagnosis and therapy of chronic pancreatitis (HaPanEU)
|United European Gastroenterology Journal|2017|698